Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer

Archive ouverte

Lavoué, Vincent | Thédrez, Aurélie | Levêque, Jean | Foucher, Fabrice | Henno, Sébastien | Jauffret, Vincent | Belaud-Rotureau, Marc-Antoine | Catros, Veronique | Cabillic, Florian

Edité par CCSD ; BioMed Central -

International audience. Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women, and there has been no substantial decrease in the death rates due to EOC in the last three decades. Thus, basic knowledge regarding ovarian tumor cell biology is urgently needed to allow the development of innovative treatments for EOC. Traditionally, EOC has not been considered an immunogenic tumor, but there is evidence of an immune response to EOC in patients. Clinical data demonstrate that an antitumor immune response and immune evasion mechanisms are correlated with a better and lower survival, respectively, providing evidence for the immunoediting hypothesis in EOC. This review focuses on the immune response and immune suppression in EOC. The immunological roles of chemotherapy and surgery in EOC are also described. Finally, we detail pilot data supporting the efficiency of immunotherapy in the treatment of EOC and the emerging concept that immunomodulation aimed at counteracting the immunosuppressive microenvironment must be associated with immunotherapy strategies.

Suggestions

Du même auteur

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.

Archive ouverte | Lavoué, Vincent | CCSD

International audience. Epithelial ovarian cancer (EOC) usually spreads into the peritoneal cavity, thereby providing an opportunity for intraperitoneal adoptive immunotherapy with Vγ9Vδ2 T lymphocytes, a T cell sub...

L'immunothérapie dans le cancer épithélial de l'ovaire : entre espoir et réalité [Immunotherapy in epithelial ovarian carcinoma: hope and reality]

Archive ouverte | Lavoué, Vincent | CCSD

National audience. Le cancer épithélial de l'ovaire (CEO) présente un pronostic sombre avec depuis deux décennies des progrès très modestes en terme de gain de survie. L'immunologie, longtemps négligée dans le CEO, ...

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non-Small-Cell Lung Cancers Reveal Major Discordances

Archive ouverte | Cabillic, Florian | CCSD

International audience. Introduction: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non-small-cell lung cancers (NSCLCs). Crizotinib, an ALK inhibitor, has been demonstrated to provide dramati...

Chargement des enrichissements...